Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03234751 · ClinicalTrials.gov registry record · Phase 1
Effect of Nesiritide Infusion on Insulin Sensitivity in Healthy Obese Insulin Resistant Subjects
A Phase 1 study, sponsored by AdventHealth Translational Research Institute.
- Completed
- Registry status
- Phase 1
- Development phase
- 6
- Enrollment target
NCT03234751 is a Phase 1 study that has completed, run by AdventHealth Translational Research Institute. The registered enrollment target is 6 participants.
The verdict
NCT03234751, a Phase 1 study, has completed, sponsored by AdventHealth Translational Research Institute.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 6 participants
- Enrollment target
Study Summary
The purpose of the study is to compare the effects of nesiritide to placebo administered by a continuous IV infusion over 48 hours for the treatment of insulin resistance in healthy, obese, insulin resistant individuals.
Interventions
- DRUG Placebo
- DRUG Hyperinsulinemic euglycemic clamp
- DRUG Continous IV infusion of Nesiritide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2017-07-13 |
| Est. Completion | 2020-02-19 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03234751
The ClinicalTrials.gov registry entry for NCT03234751 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AdventHealth Translational Research Institute, which has 54 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT03234751 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03234751 about?
NCT03234751 is a clinical study titled "Effect of Nesiritide Infusion on Insulin Sensitivity in Healthy Obese Insulin Resistant Subjects". The purpose of the study is to compare the effects of nesiritide to placebo administered by a continuous IV infusion over 48 hours for the treatment of insulin resistance in healthy, obese, insulin resistant individuals.
What is the current status of trial NCT03234751?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 6 participants. The study started on 2017-07-13. Estimated completion is 2020-02-19.
What interventions are being tested in trial NCT03234751?
The interventions under investigation include: Placebo (DRUG), Hyperinsulinemic euglycemic clamp (DRUG), Continous IV infusion of Nesiritide (DRUG).
Who is sponsoring clinical trial NCT03234751?
This trial is sponsored by AdventHealth Translational Research Institute, which has 54 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.